Konteatis, Zenon
Agios Pharmaceuticals (United States)
3 papers on CoChatORCID 0000-0002-5421-4907
Most cited papers
- Verified
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
Marjon, K., Cameron, M. J., Quang, P., Clasquin, M. F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. (2016) · Cell Reports
Cancer-related gene regulationRNA modifications and cancer
Cited by 485
- Verified
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Yen, K., Travins, J., Wang, F., David, M. D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., et al. (2017) · Cancer Discovery
Acute Myeloid Leukemia ResearchGlioma Diagnosis and Treatment
Cited by 471
- Verified
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Intlekofer, A. M., Shih, A. H., Wang, B., Nazir, A., Rustenburg, A. S., Albanese, S. K., Patel, M., Famulare, C., Correa, F. M., Takemoto, N., et al. (2018) · Nature
Acute Myeloid Leukemia ResearchGlioma Diagnosis and Treatment
Cited by 281
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free